nodes	percent_of_prediction	percent_of_DWPC	metapath
Aminosalicylic Acid—PTGS2—skin cancer	0.682	1	CbGaD
Aminosalicylic Acid—Non-Hodgkin's lymphoma—Imiquimod—skin cancer	0.00755	0.0483	CcSEcCtD
Aminosalicylic Acid—Lymphoma—Imiquimod—skin cancer	0.00755	0.0483	CcSEcCtD
Aminosalicylic Acid—MPO—endothelium—skin cancer	0.00473	0.0528	CbGeAlD
Aminosalicylic Acid—CHUK—connective tissue—skin cancer	0.00469	0.0524	CbGeAlD
Aminosalicylic Acid—PTGS2—leg—skin cancer	0.00464	0.0518	CbGeAlD
Aminosalicylic Acid—CHUK—epithelium—skin cancer	0.00445	0.0497	CbGeAlD
Aminosalicylic Acid—MPO—blood vessel—skin cancer	0.00436	0.0487	CbGeAlD
Aminosalicylic Acid—Cutaneous hypersensitivity—Docetaxel—skin cancer	0.0043	0.0276	CcSEcCtD
Aminosalicylic Acid—CHUK—skin of body—skin cancer	0.00424	0.0473	CbGeAlD
Aminosalicylic Acid—PTGS2—hindlimb—skin cancer	0.00414	0.0463	CbGeAlD
Aminosalicylic Acid—PTGS2—appendage—skin cancer	0.00355	0.0397	CbGeAlD
Aminosalicylic Acid—CHUK—lymphoid tissue—skin cancer	0.00343	0.0383	CbGeAlD
Aminosalicylic Acid—Pericarditis—Fluorouracil—skin cancer	0.00337	0.0216	CcSEcCtD
Aminosalicylic Acid—CHUK—female reproductive system—skin cancer	0.00331	0.037	CbGeAlD
Aminosalicylic Acid—Vasculitis—Vemurafenib—skin cancer	0.00317	0.0203	CcSEcCtD
Aminosalicylic Acid—PTGS2—skin epidermis—skin cancer	0.00296	0.033	CbGeAlD
Aminosalicylic Acid—Weight decreased—Vismodegib—skin cancer	0.00284	0.0182	CcSEcCtD
Aminosalicylic Acid—Eruption—Dactinomycin—skin cancer	0.00284	0.0182	CcSEcCtD
Aminosalicylic Acid—CHUK—head—skin cancer	0.00276	0.0309	CbGeAlD
Aminosalicylic Acid—ALOX5—connective tissue—skin cancer	0.00264	0.0295	CbGeAlD
Aminosalicylic Acid—Encephalopathy—Fluorouracil—skin cancer	0.00227	0.0145	CcSEcCtD
Aminosalicylic Acid—PTGS1—endothelium—skin cancer	0.00224	0.0251	CbGeAlD
Aminosalicylic Acid—MPO—connective tissue—skin cancer	0.00224	0.025	CbGeAlD
Aminosalicylic Acid—Malnutrition—Vismodegib—skin cancer	0.00219	0.014	CcSEcCtD
Aminosalicylic Acid—PTGS2—endothelium—skin cancer	0.00214	0.024	CbGeAlD
Aminosalicylic Acid—Dysgeusia—Vismodegib—skin cancer	0.00214	0.0137	CcSEcCtD
Aminosalicylic Acid—MPO—epithelium—skin cancer	0.00212	0.0237	CbGeAlD
Aminosalicylic Acid—PTGS1—blood vessel—skin cancer	0.00207	0.0231	CbGeAlD
Aminosalicylic Acid—Dermatitis exfoliative—Imiquimod—skin cancer	0.00203	0.013	CcSEcCtD
Aminosalicylic Acid—MPO—skin of body—skin cancer	0.00202	0.0226	CbGeAlD
Aminosalicylic Acid—Purpura—Imiquimod—skin cancer	0.00199	0.0127	CcSEcCtD
Aminosalicylic Acid—PTGS2—blood vessel—skin cancer	0.00198	0.0221	CbGeAlD
Aminosalicylic Acid—CHUK—lymph node—skin cancer	0.00194	0.0216	CbGeAlD
Aminosalicylic Acid—ALOX5—lymphoid tissue—skin cancer	0.00193	0.0216	CbGeAlD
Aminosalicylic Acid—ALOX5—female reproductive system—skin cancer	0.00186	0.0208	CbGeAlD
Aminosalicylic Acid—Unspecified disorder of skin and subcutaneous tissue—Vismodegib—skin cancer	0.00185	0.0118	CcSEcCtD
Aminosalicylic Acid—Weight decreased—Vemurafenib—skin cancer	0.00175	0.0112	CcSEcCtD
Aminosalicylic Acid—Nervous system disorder—Vismodegib—skin cancer	0.00175	0.0112	CcSEcCtD
Aminosalicylic Acid—Skin disorder—Vismodegib—skin cancer	0.00173	0.0111	CcSEcCtD
Aminosalicylic Acid—Eruption—Docetaxel—skin cancer	0.00171	0.0109	CcSEcCtD
Aminosalicylic Acid—Neuropathy peripheral—Vemurafenib—skin cancer	0.0017	0.0109	CcSEcCtD
Aminosalicylic Acid—MPO—lymphoid tissue—skin cancer	0.00164	0.0183	CbGeAlD
Aminosalicylic Acid—ALOX5—head—skin cancer	0.00156	0.0174	CbGeAlD
Aminosalicylic Acid—Decreased appetite—Vismodegib—skin cancer	0.00155	0.00994	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal disorder—Vismodegib—skin cancer	0.00154	0.00987	CcSEcCtD
Aminosalicylic Acid—PTGS1—nipple—skin cancer	0.0015	0.0167	CbGeAlD
Aminosalicylic Acid—Gastrointestinal pain—Vismodegib—skin cancer	0.00146	0.00935	CcSEcCtD
Aminosalicylic Acid—Neuropathy peripheral—Imiquimod—skin cancer	0.00145	0.00926	CcSEcCtD
Aminosalicylic Acid—Dermatitis atopic—Docetaxel—skin cancer	0.00142	0.00909	CcSEcCtD
Aminosalicylic Acid—Abdominal pain—Vismodegib—skin cancer	0.00141	0.00904	CcSEcCtD
Aminosalicylic Acid—Malnutrition—Vemurafenib—skin cancer	0.00135	0.00866	CcSEcCtD
Aminosalicylic Acid—Dysgeusia—Vemurafenib—skin cancer	0.00132	0.00848	CcSEcCtD
Aminosalicylic Acid—MPO—head—skin cancer	0.00132	0.0147	CbGeAlD
Aminosalicylic Acid—Urinary tract disorder—Imiquimod—skin cancer	0.00131	0.00838	CcSEcCtD
Aminosalicylic Acid—Urethral disorder—Imiquimod—skin cancer	0.0013	0.00831	CcSEcCtD
Aminosalicylic Acid—Vascular purpura—Temozolomide—skin cancer	0.00128	0.00821	CcSEcCtD
Aminosalicylic Acid—Diarrhoea—Vismodegib—skin cancer	0.00122	0.00783	CcSEcCtD
Aminosalicylic Acid—Dermatitis exfoliative—Temozolomide—skin cancer	0.00122	0.00779	CcSEcCtD
Aminosalicylic Acid—Purpura—Temozolomide—skin cancer	0.00119	0.00762	CcSEcCtD
Aminosalicylic Acid—Malnutrition—Imiquimod—skin cancer	0.00115	0.00738	CcSEcCtD
Aminosalicylic Acid—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.00114	0.00732	CcSEcCtD
Aminosalicylic Acid—Vomiting—Vismodegib—skin cancer	0.00114	0.00727	CcSEcCtD
Aminosalicylic Acid—Rash—Vismodegib—skin cancer	0.00113	0.00721	CcSEcCtD
Aminosalicylic Acid—Dermatitis—Vismodegib—skin cancer	0.00112	0.0072	CcSEcCtD
Aminosalicylic Acid—ALOX5—lymph node—skin cancer	0.00109	0.0122	CbGeAlD
Aminosalicylic Acid—Diflunisal—PTGS2—skin cancer	0.00108	0.427	CrCbGaD
Aminosalicylic Acid—Nervous system disorder—Vemurafenib—skin cancer	0.00108	0.00693	CcSEcCtD
Aminosalicylic Acid—Skin disorder—Vemurafenib—skin cancer	0.00107	0.00686	CcSEcCtD
Aminosalicylic Acid—Weight decreased—Bleomycin—skin cancer	0.00106	0.00681	CcSEcCtD
Aminosalicylic Acid—PTGS1—connective tissue—skin cancer	0.00106	0.0118	CbGeAlD
Aminosalicylic Acid—Nausea—Vismodegib—skin cancer	0.00106	0.00679	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal haemorrhage—Fluorouracil—skin cancer	0.00106	0.00677	CcSEcCtD
Aminosalicylic Acid—PTGS2—connective tissue—skin cancer	0.00101	0.0113	CbGeAlD
Aminosalicylic Acid—PTGS1—epithelium—skin cancer	0.00101	0.0112	CbGeAlD
Aminosalicylic Acid—Abdominal distension—Temozolomide—skin cancer	0.000998	0.00639	CcSEcCtD
Aminosalicylic Acid—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.000975	0.00624	CcSEcCtD
Aminosalicylic Acid—PTGS2—epithelium—skin cancer	0.000963	0.0108	CbGeAlD
Aminosalicylic Acid—Decreased appetite—Vemurafenib—skin cancer	0.000959	0.00614	CcSEcCtD
Aminosalicylic Acid—PTGS1—skin of body—skin cancer	0.000958	0.0107	CbGeAlD
Aminosalicylic Acid—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000952	0.0061	CcSEcCtD
Aminosalicylic Acid—MPO—lymph node—skin cancer	0.000923	0.0103	CbGeAlD
Aminosalicylic Acid—Nervous system disorder—Imiquimod—skin cancer	0.000922	0.00591	CcSEcCtD
Aminosalicylic Acid—PTGS2—skin of body—skin cancer	0.000916	0.0102	CbGeAlD
Aminosalicylic Acid—Skin disorder—Imiquimod—skin cancer	0.000914	0.00585	CcSEcCtD
Aminosalicylic Acid—Agranulocytosis—Dactinomycin—skin cancer	0.000912	0.00584	CcSEcCtD
Aminosalicylic Acid—Weight decreased—Temozolomide—skin cancer	0.000897	0.00575	CcSEcCtD
Aminosalicylic Acid—Anorexia—Imiquimod—skin cancer	0.000897	0.00574	CcSEcCtD
Aminosalicylic Acid—Hepatitis—Dactinomycin—skin cancer	0.000877	0.00562	CcSEcCtD
Aminosalicylic Acid—PTGS1—mammalian vulva—skin cancer	0.000874	0.00976	CbGeAlD
Aminosalicylic Acid—Body temperature increased—Vemurafenib—skin cancer	0.000872	0.00559	CcSEcCtD
Aminosalicylic Acid—Neuropathy peripheral—Temozolomide—skin cancer	0.000866	0.00555	CcSEcCtD
Aminosalicylic Acid—Mesalazine—PTGS2—skin cancer	0.000849	0.335	CrCbGaD
Aminosalicylic Acid—Decreased appetite—Imiquimod—skin cancer	0.000818	0.00524	CcSEcCtD
Aminosalicylic Acid—Hypersensitivity—Vemurafenib—skin cancer	0.000813	0.00521	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal disorder—Imiquimod—skin cancer	0.000812	0.0052	CcSEcCtD
Aminosalicylic Acid—Neuropathy peripheral—Fluorouracil—skin cancer	0.000798	0.00511	CcSEcCtD
Aminosalicylic Acid—Hepatitis—Temozolomide—skin cancer	0.000793	0.00508	CcSEcCtD
Aminosalicylic Acid—Urinary tract disorder—Temozolomide—skin cancer	0.000784	0.00502	CcSEcCtD
Aminosalicylic Acid—Urethral disorder—Temozolomide—skin cancer	0.000778	0.00498	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal pain—Imiquimod—skin cancer	0.000769	0.00493	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal haemorrhage—Docetaxel—skin cancer	0.000763	0.00489	CcSEcCtD
Aminosalicylic Acid—Agranulocytosis—Fluorouracil—skin cancer	0.00076	0.00487	CcSEcCtD
Aminosalicylic Acid—Anaemia—Bleomycin—skin cancer	0.000757	0.00485	CcSEcCtD
Aminosalicylic Acid—Diarrhoea—Vemurafenib—skin cancer	0.000755	0.00483	CcSEcCtD
Aminosalicylic Acid—PTGS1—female reproductive system—skin cancer	0.000748	0.00836	CbGeAlD
Aminosalicylic Acid—Urticaria—Imiquimod—skin cancer	0.000747	0.00479	CcSEcCtD
Aminosalicylic Acid—Abdominal pain—Imiquimod—skin cancer	0.000744	0.00476	CcSEcCtD
Aminosalicylic Acid—Body temperature increased—Imiquimod—skin cancer	0.000744	0.00476	CcSEcCtD
Aminosalicylic Acid—PTGS2—lymphoid tissue—skin cancer	0.000742	0.00828	CbGeAlD
Aminosalicylic Acid—Leukopenia—Bleomycin—skin cancer	0.000733	0.0047	CcSEcCtD
Aminosalicylic Acid—Dizziness—Vemurafenib—skin cancer	0.000729	0.00467	CcSEcCtD
Aminosalicylic Acid—PTGS2—female reproductive system—skin cancer	0.000715	0.00799	CbGeAlD
Aminosalicylic Acid—Anaemia—Dactinomycin—skin cancer	0.000706	0.00452	CcSEcCtD
Aminosalicylic Acid—Vomiting—Vemurafenib—skin cancer	0.000701	0.00449	CcSEcCtD
Aminosalicylic Acid—Rash—Vemurafenib—skin cancer	0.000695	0.00446	CcSEcCtD
Aminosalicylic Acid—Dermatitis—Vemurafenib—skin cancer	0.000695	0.00445	CcSEcCtD
Aminosalicylic Acid—Hypersensitivity—Imiquimod—skin cancer	0.000693	0.00444	CcSEcCtD
Aminosalicylic Acid—Headache—Vemurafenib—skin cancer	0.000691	0.00443	CcSEcCtD
Aminosalicylic Acid—Malnutrition—Temozolomide—skin cancer	0.000691	0.00442	CcSEcCtD
Aminosalicylic Acid—Leukopenia—Dactinomycin—skin cancer	0.000684	0.00438	CcSEcCtD
Aminosalicylic Acid—Dysgeusia—Temozolomide—skin cancer	0.000676	0.00433	CcSEcCtD
Aminosalicylic Acid—Nausea—Vemurafenib—skin cancer	0.000655	0.0042	CcSEcCtD
Aminosalicylic Acid—Thrombocytopenia—Bleomycin—skin cancer	0.000654	0.00419	CcSEcCtD
Aminosalicylic Acid—Diarrhoea—Imiquimod—skin cancer	0.000644	0.00412	CcSEcCtD
Aminosalicylic Acid—Anaemia—Temozolomide—skin cancer	0.000638	0.00409	CcSEcCtD
Aminosalicylic Acid—Anorexia—Bleomycin—skin cancer	0.000637	0.00408	CcSEcCtD
Aminosalicylic Acid—PTGS1—head—skin cancer	0.000625	0.00698	CbGeAlD
Aminosalicylic Acid—Dizziness—Imiquimod—skin cancer	0.000622	0.00398	CcSEcCtD
Aminosalicylic Acid—Leukopenia—Temozolomide—skin cancer	0.000618	0.00396	CcSEcCtD
Aminosalicylic Acid—Thrombocytopenia—Dactinomycin—skin cancer	0.00061	0.00391	CcSEcCtD
Aminosalicylic Acid—Salicylic acid—PTGS2—skin cancer	0.000602	0.238	CrCbGaD
Aminosalicylic Acid—Vomiting—Imiquimod—skin cancer	0.000598	0.00383	CcSEcCtD
Aminosalicylic Acid—PTGS2—head—skin cancer	0.000598	0.00667	CbGeAlD
Aminosalicylic Acid—Weight decreased—Docetaxel—skin cancer	0.000596	0.00382	CcSEcCtD
Aminosalicylic Acid—Anorexia—Dactinomycin—skin cancer	0.000594	0.00381	CcSEcCtD
Aminosalicylic Acid—Rash—Imiquimod—skin cancer	0.000593	0.0038	CcSEcCtD
Aminosalicylic Acid—Dermatitis—Imiquimod—skin cancer	0.000593	0.0038	CcSEcCtD
Aminosalicylic Acid—Headache—Imiquimod—skin cancer	0.000589	0.00378	CcSEcCtD
Aminosalicylic Acid—Anaemia—Fluorouracil—skin cancer	0.000588	0.00377	CcSEcCtD
Aminosalicylic Acid—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000584	0.00374	CcSEcCtD
Aminosalicylic Acid—Decreased appetite—Bleomycin—skin cancer	0.000581	0.00372	CcSEcCtD
Aminosalicylic Acid—Neuropathy peripheral—Docetaxel—skin cancer	0.000576	0.00369	CcSEcCtD
Aminosalicylic Acid—Jaundice—Docetaxel—skin cancer	0.000573	0.00367	CcSEcCtD
Aminosalicylic Acid—Leukopenia—Fluorouracil—skin cancer	0.00057	0.00365	CcSEcCtD
Aminosalicylic Acid—Nausea—Imiquimod—skin cancer	0.000559	0.00358	CcSEcCtD
Aminosalicylic Acid—Nervous system disorder—Temozolomide—skin cancer	0.000553	0.00354	CcSEcCtD
Aminosalicylic Acid—Thrombocytopenia—Temozolomide—skin cancer	0.000552	0.00354	CcSEcCtD
Aminosalicylic Acid—Agranulocytosis—Docetaxel—skin cancer	0.000549	0.00351	CcSEcCtD
Aminosalicylic Acid—Skin disorder—Temozolomide—skin cancer	0.000548	0.00351	CcSEcCtD
Aminosalicylic Acid—Decreased appetite—Dactinomycin—skin cancer	0.000542	0.00347	CcSEcCtD
Aminosalicylic Acid—Anorexia—Temozolomide—skin cancer	0.000537	0.00344	CcSEcCtD
Aminosalicylic Acid—Urticaria—Bleomycin—skin cancer	0.000531	0.0034	CcSEcCtD
Aminosalicylic Acid—Body temperature increased—Bleomycin—skin cancer	0.000528	0.00338	CcSEcCtD
Aminosalicylic Acid—Hepatitis—Docetaxel—skin cancer	0.000528	0.00338	CcSEcCtD
Aminosalicylic Acid—Urinary tract disorder—Docetaxel—skin cancer	0.000521	0.00334	CcSEcCtD
Aminosalicylic Acid—Urethral disorder—Docetaxel—skin cancer	0.000517	0.00331	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal pain—Dactinomycin—skin cancer	0.00051	0.00326	CcSEcCtD
Aminosalicylic Acid—Nervous system disorder—Fluorouracil—skin cancer	0.000509	0.00326	CcSEcCtD
Aminosalicylic Acid—Thrombocytopenia—Fluorouracil—skin cancer	0.000509	0.00326	CcSEcCtD
Aminosalicylic Acid—Anorexia—Fluorouracil—skin cancer	0.000495	0.00317	CcSEcCtD
Aminosalicylic Acid—Abdominal pain—Dactinomycin—skin cancer	0.000493	0.00316	CcSEcCtD
Aminosalicylic Acid—Body temperature increased—Dactinomycin—skin cancer	0.000493	0.00316	CcSEcCtD
Aminosalicylic Acid—Hypersensitivity—Bleomycin—skin cancer	0.000492	0.00315	CcSEcCtD
Aminosalicylic Acid—Decreased appetite—Temozolomide—skin cancer	0.00049	0.00314	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal disorder—Temozolomide—skin cancer	0.000487	0.00312	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal pain—Temozolomide—skin cancer	0.000461	0.00295	CcSEcCtD
Aminosalicylic Acid—Malnutrition—Docetaxel—skin cancer	0.000459	0.00294	CcSEcCtD
Aminosalicylic Acid—Hypersensitivity—Dactinomycin—skin cancer	0.000459	0.00294	CcSEcCtD
Aminosalicylic Acid—Decreased appetite—Fluorouracil—skin cancer	0.000452	0.00289	CcSEcCtD
Aminosalicylic Acid—Dysgeusia—Docetaxel—skin cancer	0.00045	0.00288	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000448	0.00287	CcSEcCtD
Aminosalicylic Acid—Urticaria—Temozolomide—skin cancer	0.000448	0.00287	CcSEcCtD
Aminosalicylic Acid—Abdominal pain—Temozolomide—skin cancer	0.000446	0.00285	CcSEcCtD
Aminosalicylic Acid—Body temperature increased—Temozolomide—skin cancer	0.000446	0.00285	CcSEcCtD
Aminosalicylic Acid—PTGS1—lymph node—skin cancer	0.000438	0.00489	CbGeAlD
Aminosalicylic Acid—Diarrhoea—Dactinomycin—skin cancer	0.000426	0.00273	CcSEcCtD
Aminosalicylic Acid—Vomiting—Bleomycin—skin cancer	0.000425	0.00272	CcSEcCtD
Aminosalicylic Acid—Anaemia—Docetaxel—skin cancer	0.000425	0.00272	CcSEcCtD
Aminosalicylic Acid—Rash—Bleomycin—skin cancer	0.000421	0.0027	CcSEcCtD
Aminosalicylic Acid—Dermatitis—Bleomycin—skin cancer	0.000421	0.0027	CcSEcCtD
Aminosalicylic Acid—PTGS2—lymph node—skin cancer	0.000418	0.00467	CbGeAlD
Aminosalicylic Acid—Hypersensitivity—Temozolomide—skin cancer	0.000415	0.00266	CcSEcCtD
Aminosalicylic Acid—Urticaria—Fluorouracil—skin cancer	0.000413	0.00264	CcSEcCtD
Aminosalicylic Acid—Leukopenia—Docetaxel—skin cancer	0.000411	0.00263	CcSEcCtD
Aminosalicylic Acid—Body temperature increased—Fluorouracil—skin cancer	0.000411	0.00263	CcSEcCtD
Aminosalicylic Acid—Nausea—Bleomycin—skin cancer	0.000397	0.00254	CcSEcCtD
Aminosalicylic Acid—Vomiting—Dactinomycin—skin cancer	0.000396	0.00254	CcSEcCtD
Aminosalicylic Acid—Rash—Dactinomycin—skin cancer	0.000393	0.00252	CcSEcCtD
Aminosalicylic Acid—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000388	0.00249	CcSEcCtD
Aminosalicylic Acid—Diarrhoea—Temozolomide—skin cancer	0.000386	0.00247	CcSEcCtD
Aminosalicylic Acid—Hypersensitivity—Fluorouracil—skin cancer	0.000383	0.00245	CcSEcCtD
Aminosalicylic Acid—Dizziness—Temozolomide—skin cancer	0.000373	0.00239	CcSEcCtD
Aminosalicylic Acid—Nausea—Dactinomycin—skin cancer	0.00037	0.00237	CcSEcCtD
Aminosalicylic Acid—Nervous system disorder—Docetaxel—skin cancer	0.000368	0.00236	CcSEcCtD
Aminosalicylic Acid—Thrombocytopenia—Docetaxel—skin cancer	0.000367	0.00235	CcSEcCtD
Aminosalicylic Acid—Skin disorder—Docetaxel—skin cancer	0.000364	0.00233	CcSEcCtD
Aminosalicylic Acid—Vomiting—Temozolomide—skin cancer	0.000358	0.0023	CcSEcCtD
Aminosalicylic Acid—Anorexia—Docetaxel—skin cancer	0.000357	0.00229	CcSEcCtD
Aminosalicylic Acid—Rash—Temozolomide—skin cancer	0.000355	0.00228	CcSEcCtD
Aminosalicylic Acid—Diarrhoea—Fluorouracil—skin cancer	0.000355	0.00228	CcSEcCtD
Aminosalicylic Acid—Dermatitis—Temozolomide—skin cancer	0.000355	0.00227	CcSEcCtD
Aminosalicylic Acid—Headache—Temozolomide—skin cancer	0.000353	0.00226	CcSEcCtD
Aminosalicylic Acid—CHUK—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	0.000351	0.005	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Downstream signal transduction—FOXO4—skin cancer	0.000346	0.00493	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by FGFR—FOXO4—skin cancer	0.000344	0.00491	CbGpPWpGaD
Aminosalicylic Acid—Dizziness—Fluorouracil—skin cancer	0.000343	0.0022	CcSEcCtD
Aminosalicylic Acid—CHUK—Signaling by ERBB2—FOXO4—skin cancer	0.000343	0.00488	CbGpPWpGaD
Aminosalicylic Acid—CHUK—DAP12 signaling—FOXO4—skin cancer	0.000341	0.00486	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Downstream signaling events of B Cell Receptor (BCR)—FOXO4—skin cancer	0.000336	0.00479	CbGpPWpGaD
Aminosalicylic Acid—Nausea—Temozolomide—skin cancer	0.000335	0.00215	CcSEcCtD
Aminosalicylic Acid—PTGS1—Overview of nanoparticle effects—IL6—skin cancer	0.000332	0.00473	CbGpPWpGaD
Aminosalicylic Acid—Vomiting—Fluorouracil—skin cancer	0.00033	0.00212	CcSEcCtD
Aminosalicylic Acid—Rash—Fluorouracil—skin cancer	0.000327	0.0021	CcSEcCtD
Aminosalicylic Acid—MPO—Folate Metabolism—TP53—skin cancer	0.000327	0.00467	CbGpPWpGaD
Aminosalicylic Acid—Dermatitis—Fluorouracil—skin cancer	0.000327	0.0021	CcSEcCtD
Aminosalicylic Acid—Decreased appetite—Docetaxel—skin cancer	0.000326	0.00209	CcSEcCtD
Aminosalicylic Acid—Headache—Fluorouracil—skin cancer	0.000325	0.00208	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal disorder—Docetaxel—skin cancer	0.000324	0.00207	CcSEcCtD
Aminosalicylic Acid—CHUK—Signaling by FGFR in disease—FOXO4—skin cancer	0.000321	0.00457	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Fc epsilon receptor (FCERI) signaling—FOXO4—skin cancer	0.000321	0.00457	CbGpPWpGaD
Aminosalicylic Acid—CHUK—DAP12 interactions—FOXO4—skin cancer	0.000321	0.00457	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by EGFR—FOXO4—skin cancer	0.000318	0.00453	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by EGFR in Cancer—FOXO4—skin cancer	0.000315	0.00449	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by PDGF—FOXO4—skin cancer	0.000314	0.00447	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—skin cancer	0.000312	0.00445	CbGpPWpGaD
Aminosalicylic Acid—Nausea—Fluorouracil—skin cancer	0.000309	0.00198	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal pain—Docetaxel—skin cancer	0.000307	0.00196	CcSEcCtD
Aminosalicylic Acid—MPO—C-MYB transcription factor network—KRAS—skin cancer	0.000304	0.00433	CbGpPWpGaD
Aminosalicylic Acid—PLA2G2E—Metabolism—ENO2—skin cancer	0.000302	0.00431	CbGpPWpGaD
Aminosalicylic Acid—MPO—Folate Metabolism—IL6—skin cancer	0.0003	0.00427	CbGpPWpGaD
Aminosalicylic Acid—CHUK—B Cell Activation—FOXO4—skin cancer	0.000297	0.00423	CbGpPWpGaD
Aminosalicylic Acid—Body temperature increased—Docetaxel—skin cancer	0.000296	0.0019	CcSEcCtD
Aminosalicylic Acid—Abdominal pain—Docetaxel—skin cancer	0.000296	0.0019	CcSEcCtD
Aminosalicylic Acid—CHUK—NGF signalling via TRKA from the plasma membrane—FOXO4—skin cancer	0.000284	0.00405	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Arachidonic acid metabolism—PTGS2—skin cancer	0.000281	0.00401	CbGpPWpGaD
Aminosalicylic Acid—CHUK—TCR signaling in naïve CD8+ T cells—NRAS—skin cancer	0.00028	0.00399	CbGpPWpGaD
Aminosalicylic Acid—Hypersensitivity—Docetaxel—skin cancer	0.000276	0.00177	CcSEcCtD
Aminosalicylic Acid—CHUK—B Cell Receptor Signaling Pathway—BRAF—skin cancer	0.000274	0.00391	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Apoptosis—CDKN2A—skin cancer	0.000266	0.00379	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Overview of nanoparticle effects—IL6—skin cancer	0.000264	0.00376	CbGpPWpGaD
Aminosalicylic Acid—CHUK—PDGF Pathway—HRAS—skin cancer	0.000262	0.00373	CbGpPWpGaD
Aminosalicylic Acid—MPO—C-MYB transcription factor network—HRAS—skin cancer	0.000258	0.00368	CbGpPWpGaD
Aminosalicylic Acid—Diarrhoea—Docetaxel—skin cancer	0.000256	0.00164	CcSEcCtD
Aminosalicylic Acid—Dizziness—Docetaxel—skin cancer	0.000248	0.00159	CcSEcCtD
Aminosalicylic Acid—CHUK—Innate Immune System—TLR7—skin cancer	0.000242	0.00345	CbGpPWpGaD
Aminosalicylic Acid—CHUK—TCR signaling in naïve CD8+ T cells—KRAS—skin cancer	0.000241	0.00343	CbGpPWpGaD
Aminosalicylic Acid—Vomiting—Docetaxel—skin cancer	0.000238	0.00153	CcSEcCtD
Aminosalicylic Acid—MPO—Selenium Micronutrient Network—IL6—skin cancer	0.000238	0.00339	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Interleukin-11 Signaling Pathway—HRAS—skin cancer	0.000238	0.00338	CbGpPWpGaD
Aminosalicylic Acid—PLA2G2E—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	0.000236	0.00337	CbGpPWpGaD
Aminosalicylic Acid—Rash—Docetaxel—skin cancer	0.000236	0.00151	CcSEcCtD
Aminosalicylic Acid—Dermatitis—Docetaxel—skin cancer	0.000236	0.00151	CcSEcCtD
Aminosalicylic Acid—CHUK—TWEAK Signaling Pathway—IL6—skin cancer	0.000236	0.00336	CbGpPWpGaD
Aminosalicylic Acid—Headache—Docetaxel—skin cancer	0.000235	0.0015	CcSEcCtD
Aminosalicylic Acid—CHUK—TCR signaling in naïve CD4+ T cells—NRAS—skin cancer	0.000235	0.00334	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Rac1/Pak1/p38/MMP-2 pathway—NRAS—skin cancer	0.000232	0.0033	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—RHOU—skin cancer	0.000229	0.00326	CbGpPWpGaD
Aminosalicylic Acid—ALOX5—Selenium Micronutrient Network—IL6—skin cancer	0.000225	0.0032	CbGpPWpGaD
Aminosalicylic Acid—Nausea—Docetaxel—skin cancer	0.000223	0.00143	CcSEcCtD
Aminosalicylic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	0.000219	0.00312	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by NGF—FOXO4—skin cancer	0.000218	0.00311	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Integrated Breast Cancer Pathway—CDK4—skin cancer	0.000218	0.0031	CbGpPWpGaD
Aminosalicylic Acid—ALOX5—Metabolism—PLIN2—skin cancer	0.000216	0.00308	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	0.000211	0.003	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	0.000208	0.00296	CbGpPWpGaD
Aminosalicylic Acid—CHUK—TCR signaling in naïve CD8+ T cells—HRAS—skin cancer	0.000205	0.00292	CbGpPWpGaD
Aminosalicylic Acid—CHUK—TCR signaling in naïve CD4+ T cells—KRAS—skin cancer	0.000202	0.00288	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Rac1/Pak1/p38/MMP-2 pathway—KRAS—skin cancer	0.0002	0.00284	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Integrated Breast Cancer Pathway—BRAF—skin cancer	0.000193	0.00275	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Aryl Hydrocarbon Receptor—NRAS—skin cancer	0.000186	0.00264	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Fc-epsilon receptor I signaling in mast cells—HRAS—skin cancer	0.000183	0.00261	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by FGFR—BRAF—skin cancer	0.000182	0.00259	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	0.00018	0.00257	CbGpPWpGaD
Aminosalicylic Acid—CHUK—TNF alpha Signaling Pathway—NRAS—skin cancer	0.00018	0.00256	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Selenium Micronutrient Network—PTGS2—skin cancer	0.000179	0.00255	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Rac1/Pak1/p38/MMP-2 pathway—TP53—skin cancer	0.000177	0.00253	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—skin cancer	0.000177	0.00252	CbGpPWpGaD
Aminosalicylic Acid—PLA2G2E—Metabolism—ERCC2—skin cancer	0.000176	0.0025	CbGpPWpGaD
Aminosalicylic Acid—ALOX5—Metabolism—CSPG4—skin cancer	0.000174	0.00248	CbGpPWpGaD
Aminosalicylic Acid—CHUK—p75(NTR)-mediated signaling—TP53—skin cancer	0.000173	0.00247	CbGpPWpGaD
Aminosalicylic Acid—CHUK—TCR signaling in naïve CD4+ T cells—HRAS—skin cancer	0.000172	0.00245	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Rac1/Pak1/p38/MMP-2 pathway—HRAS—skin cancer	0.00017	0.00242	CbGpPWpGaD
Aminosalicylic Acid—CHUK—BCR signaling pathway—HRAS—skin cancer	0.00017	0.00242	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by FGFR in disease—BRAF—skin cancer	0.00017	0.00242	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	0.000167	0.00238	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Aryl Hydrocarbon Receptor—KRAS—skin cancer	0.00016	0.00228	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by Interleukins—NRAS—skin cancer	0.000158	0.00226	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—C-MYB transcription factor network—CDKN2A—skin cancer	0.000158	0.00225	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Spinal Cord Injury—CDK4—skin cancer	0.000157	0.00224	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Leptin signaling pathway—HRAS—skin cancer	0.000155	0.00221	CbGpPWpGaD
Aminosalicylic Acid—CHUK—TNF alpha Signaling Pathway—KRAS—skin cancer	0.000155	0.00221	CbGpPWpGaD
Aminosalicylic Acid—CHUK—NGF signalling via TRKA from the plasma membrane—BRAF—skin cancer	0.00015	0.00214	CbGpPWpGaD
Aminosalicylic Acid—CHUK—TRAF6 Mediated Induction of proinflammatory cytokines—IL6—skin cancer	0.000148	0.00211	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Apoptosis—TP53—skin cancer	0.000148	0.00211	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—TLR7—skin cancer	0.000141	0.00201	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by Interleukins—KRAS—skin cancer	0.000136	0.00194	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Aryl Hydrocarbon Receptor—HRAS—skin cancer	0.000136	0.00193	CbGpPWpGaD
Aminosalicylic Acid—CHUK—MyD88 cascade initiated on plasma membrane—IL6—skin cancer	0.000134	0.00191	CbGpPWpGaD
Aminosalicylic Acid—CHUK—TCR Signaling Pathway—HRAS—skin cancer	0.000134	0.00191	CbGpPWpGaD
Aminosalicylic Acid—CHUK—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—IL6—skin cancer	0.000133	0.0019	CbGpPWpGaD
Aminosalicylic Acid—CHUK—TNF alpha Signaling Pathway—HRAS—skin cancer	0.000132	0.00188	CbGpPWpGaD
Aminosalicylic Acid—CHUK—MyD88 dependent cascade initiated on endosome—IL6—skin cancer	0.000131	0.00186	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	0.000129	0.00184	CbGpPWpGaD
Aminosalicylic Acid—CHUK—TCR Signaling Pathway—IL6—skin cancer	0.000128	0.00183	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by SCF-KIT—NRAS—skin cancer	0.000128	0.00182	CbGpPWpGaD
Aminosalicylic Acid—CHUK—B Cell Receptor Signaling Pathway—HRAS—skin cancer	0.000126	0.0018	CbGpPWpGaD
Aminosalicylic Acid—CHUK—TNF alpha Signaling Pathway—IL6—skin cancer	0.000126	0.0018	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Toll Like Receptor 9 (TLR9) Cascade—IL6—skin cancer	0.000126	0.0018	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Innate Immune System—FOXO4—skin cancer	0.000125	0.00178	CbGpPWpGaD
Aminosalicylic Acid—CHUK—MyD88:Mal cascade initiated on plasma membrane—IL6—skin cancer	0.000124	0.00176	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Downstream signaling of activated FGFR—NRAS—skin cancer	0.000122	0.00174	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—CSPG4—skin cancer	0.000121	0.00172	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by ERBB4—NRAS—skin cancer	0.00012	0.00172	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Adaptive Immune System—FOXO4—skin cancer	0.00012	0.00171	CbGpPWpGaD
Aminosalicylic Acid—CHUK—MyD88-independent cascade—IL6—skin cancer	0.000119	0.00169	CbGpPWpGaD
Aminosalicylic Acid—ALOX5—Metabolism—ENO2—skin cancer	0.000118	0.00169	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Toll-like Receptor Signaling Pathway—IL6—skin cancer	0.000116	0.00165	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by Interleukins—HRAS—skin cancer	0.000116	0.00165	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by NGF—BRAF—skin cancer	0.000116	0.00165	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Downstream signal transduction—NRAS—skin cancer	0.000115	0.00164	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—C-MYB transcription factor network—NRAS—skin cancer	0.000115	0.00163	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by FGFR—NRAS—skin cancer	0.000114	0.00163	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by ERBB2—NRAS—skin cancer	0.000114	0.00162	CbGpPWpGaD
Aminosalicylic Acid—CHUK—DAP12 signaling—NRAS—skin cancer	0.000113	0.00161	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—PTCH2—skin cancer	0.000112	0.00159	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Downstream signaling events of B Cell Receptor (BCR)—NRAS—skin cancer	0.000112	0.00159	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by Interleukins—IL6—skin cancer	0.000111	0.00158	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by SCF-KIT—KRAS—skin cancer	0.00011	0.00157	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Activated TLR4 signalling—IL6—skin cancer	0.000107	0.00152	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	0.000107	0.00152	CbGpPWpGaD
Aminosalicylic Acid—CHUK—DAP12 interactions—NRAS—skin cancer	0.000107	0.00152	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by FGFR in disease—NRAS—skin cancer	0.000107	0.00152	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Fc epsilon receptor (FCERI) signaling—NRAS—skin cancer	0.000107	0.00152	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by EGFR—NRAS—skin cancer	0.000106	0.00151	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Downstream signaling of activated FGFR—KRAS—skin cancer	0.000105	0.0015	CbGpPWpGaD
Aminosalicylic Acid—PLA2G2E—Metabolism—PTGS2—skin cancer	0.000105	0.0015	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by EGFR in Cancer—NRAS—skin cancer	0.000105	0.00149	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by PDGF—NRAS—skin cancer	0.000104	0.00149	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Integrated Breast Cancer Pathway—KRAS—skin cancer	0.000104	0.00148	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by ERBB4—KRAS—skin cancer	0.000104	0.00148	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Toll Like Receptor 4 (TLR4) Cascade—IL6—skin cancer	0.000101	0.00143	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Downstream signal transduction—KRAS—skin cancer	9.9e-05	0.00141	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—C-MYB transcription factor network—KRAS—skin cancer	9.87e-05	0.00141	CbGpPWpGaD
Aminosalicylic Acid—CHUK—B Cell Activation—NRAS—skin cancer	9.87e-05	0.00141	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by FGFR—KRAS—skin cancer	9.85e-05	0.0014	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by ERBB2—KRAS—skin cancer	9.8e-05	0.0014	CbGpPWpGaD
Aminosalicylic Acid—CHUK—DAP12 signaling—KRAS—skin cancer	9.75e-05	0.00139	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Selenium Micronutrient Network—IL6—skin cancer	9.74e-05	0.00139	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Downstream signaling events of B Cell Receptor (BCR)—KRAS—skin cancer	9.61e-05	0.00137	CbGpPWpGaD
Aminosalicylic Acid—CHUK—NGF signalling via TRKA from the plasma membrane—NRAS—skin cancer	9.44e-05	0.00135	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—PLIN2—skin cancer	9.38e-05	0.00134	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by SCF-KIT—HRAS—skin cancer	9.36e-05	0.00133	CbGpPWpGaD
Aminosalicylic Acid—ALOX5—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	9.27e-05	0.00132	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Integrated Breast Cancer Pathway—TP53—skin cancer	9.26e-05	0.00132	CbGpPWpGaD
Aminosalicylic Acid—CHUK—BDNF signaling pathway—HRAS—skin cancer	9.2e-05	0.00131	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by FGFR in disease—KRAS—skin cancer	9.18e-05	0.00131	CbGpPWpGaD
Aminosalicylic Acid—CHUK—DAP12 interactions—KRAS—skin cancer	9.18e-05	0.00131	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Fc epsilon receptor (FCERI) signaling—KRAS—skin cancer	9.18e-05	0.00131	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by EGFR—KRAS—skin cancer	9.09e-05	0.0013	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Regulation of toll-like receptor signaling pathway—IL6—skin cancer	9.06e-05	0.00129	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by EGFR in Cancer—KRAS—skin cancer	9.01e-05	0.00128	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by PDGF—KRAS—skin cancer	8.97e-05	0.00128	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Toll-Like Receptors Cascades—IL6—skin cancer	8.96e-05	0.00128	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by SCF-KIT—IL6—skin cancer	8.96e-05	0.00128	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Downstream signaling of activated FGFR—HRAS—skin cancer	8.95e-05	0.00128	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by ERBB4—HRAS—skin cancer	8.81e-05	0.00126	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	8.63e-05	0.00123	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Downstream signaling of activated FGFR—IL6—skin cancer	8.57e-05	0.00122	CbGpPWpGaD
Aminosalicylic Acid—CHUK—B Cell Activation—KRAS—skin cancer	8.49e-05	0.00121	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—GLI2—skin cancer	8.47e-05	0.00121	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by ERBB4—IL6—skin cancer	8.43e-05	0.0012	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Downstream signal transduction—HRAS—skin cancer	8.41e-05	0.0012	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—C-MYB transcription factor network—HRAS—skin cancer	8.39e-05	0.0012	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by FGFR—HRAS—skin cancer	8.37e-05	0.00119	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by ERBB2—HRAS—skin cancer	8.33e-05	0.00119	CbGpPWpGaD
Aminosalicylic Acid—CHUK—DAP12 signaling—HRAS—skin cancer	8.29e-05	0.00118	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—ENO2—skin cancer	8.22e-05	0.00117	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—SHH—skin cancer	8.22e-05	0.00117	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Downstream signaling events of B Cell Receptor (BCR)—HRAS—skin cancer	8.17e-05	0.00116	CbGpPWpGaD
Aminosalicylic Acid—CHUK—NGF signalling via TRKA from the plasma membrane—KRAS—skin cancer	8.13e-05	0.00116	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—MC1R—skin cancer	8.08e-05	0.00115	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Downstream signal transduction—IL6—skin cancer	8.05e-05	0.00115	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by FGFR—IL6—skin cancer	8.01e-05	0.00114	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by ERBB2—IL6—skin cancer	7.97e-05	0.00114	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—GLI1—skin cancer	7.96e-05	0.00113	CbGpPWpGaD
Aminosalicylic Acid—CHUK—DAP12 signaling—IL6—skin cancer	7.94e-05	0.00113	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Fc epsilon receptor (FCERI) signaling—HRAS—skin cancer	7.8e-05	0.00111	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by FGFR in disease—HRAS—skin cancer	7.8e-05	0.00111	CbGpPWpGaD
Aminosalicylic Acid—CHUK—DAP12 interactions—HRAS—skin cancer	7.8e-05	0.00111	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Selenium Micronutrient Network—IL6—skin cancer	7.73e-05	0.0011	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by EGFR—HRAS—skin cancer	7.73e-05	0.0011	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	7.67e-05	0.00109	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by EGFR in Cancer—HRAS—skin cancer	7.66e-05	0.00109	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by PDGF—HRAS—skin cancer	7.63e-05	0.00109	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—CSPG4—skin cancer	7.56e-05	0.00108	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—SUFU—skin cancer	7.55e-05	0.00108	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by FGFR in disease—IL6—skin cancer	7.47e-05	0.00106	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Fc epsilon receptor (FCERI) signaling—IL6—skin cancer	7.47e-05	0.00106	CbGpPWpGaD
Aminosalicylic Acid—CHUK—DAP12 interactions—IL6—skin cancer	7.47e-05	0.00106	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—PLIN2—skin cancer	7.44e-05	0.00106	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by EGFR—IL6—skin cancer	7.4e-05	0.00105	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Cytokine Signaling in Immune system—NRAS—skin cancer	7.39e-05	0.00105	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by EGFR in Cancer—IL6—skin cancer	7.33e-05	0.00104	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by PDGF—IL6—skin cancer	7.3e-05	0.00104	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by NGF—NRAS—skin cancer	7.26e-05	0.00103	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—FOXO4—skin cancer	7.26e-05	0.00103	CbGpPWpGaD
Aminosalicylic Acid—CHUK—B Cell Activation—HRAS—skin cancer	7.22e-05	0.00103	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—CSPG4—skin cancer	7.16e-05	0.00102	CbGpPWpGaD
Aminosalicylic Acid—CHUK—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	6.91e-05	0.000984	CbGpPWpGaD
Aminosalicylic Acid—ALOX5—Metabolism—ERCC2—skin cancer	6.88e-05	0.000981	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—FOXO4—skin cancer	6.7e-05	0.000955	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Spinal Cord Injury—TP53—skin cancer	6.68e-05	0.000952	CbGpPWpGaD
Aminosalicylic Acid—CHUK—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	6.61e-05	0.000942	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Cytokine Signaling in Immune system—KRAS—skin cancer	6.36e-05	0.000906	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by NGF—KRAS—skin cancer	6.25e-05	0.000891	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Spinal Cord Injury—IL6—skin cancer	6.12e-05	0.000872	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—CSPG4—skin cancer	6e-05	0.000855	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—SHH—skin cancer	5.76e-05	0.00082	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—RASA1—skin cancer	5.72e-05	0.000815	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—SMO—skin cancer	5.46e-05	0.000778	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—PTCH1—skin cancer	5.46e-05	0.000778	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Cytokine Signaling in Immune system—HRAS—skin cancer	5.4e-05	0.00077	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by NGF—HRAS—skin cancer	5.31e-05	0.000757	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—PTGER4—skin cancer	5.31e-05	0.000757	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Cytokine Signaling in Immune system—IL6—skin cancer	5.17e-05	0.000737	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—ENO2—skin cancer	5.14e-05	0.000732	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	5.11e-05	0.000729	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by NGF—IL6—skin cancer	5.09e-05	0.000725	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—SHH—skin cancer	4.87e-05	0.000694	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—ENO2—skin cancer	4.87e-05	0.000694	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—ERCC2—skin cancer	4.78e-05	0.00068	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—FOXO4—skin cancer	4.69e-05	0.000669	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	4.55e-05	0.000648	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—TERT—skin cancer	4.48e-05	0.000638	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Innate Immune System—NRAS—skin cancer	4.14e-05	0.00059	CbGpPWpGaD
Aminosalicylic Acid—ALOX5—Metabolism—PTGS2—skin cancer	4.13e-05	0.000588	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—ENO2—skin cancer	4.08e-05	0.000581	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	4.02e-05	0.000572	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Adaptive Immune System—NRAS—skin cancer	3.98e-05	0.000567	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—FOXO4—skin cancer	3.97e-05	0.000566	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Innate Immune System—KRAS—skin cancer	3.57e-05	0.000508	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—BRAF—skin cancer	3.54e-05	0.000505	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Adaptive Immune System—KRAS—skin cancer	3.42e-05	0.000488	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—TERT—skin cancer	3.13e-05	0.000447	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Innate Immune System—HRAS—skin cancer	3.03e-05	0.000432	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—ERCC2—skin cancer	2.98e-05	0.000425	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Adaptive Immune System—HRAS—skin cancer	2.91e-05	0.000415	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Innate Immune System—IL6—skin cancer	2.9e-05	0.000413	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—PTGS2—skin cancer	2.86e-05	0.000408	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—ERCC2—skin cancer	2.83e-05	0.000403	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—TERT—skin cancer	2.65e-05	0.000378	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—BRAF—skin cancer	2.48e-05	0.000354	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—NRAS—skin cancer	2.41e-05	0.000344	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—ERCC2—skin cancer	2.37e-05	0.000338	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—NRAS—skin cancer	2.23e-05	0.000317	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—BRAF—skin cancer	2.1e-05	0.000299	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—KRAS—skin cancer	2.08e-05	0.000296	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—KRAS—skin cancer	1.92e-05	0.000273	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—PTGS2—skin cancer	1.79e-05	0.000255	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—HRAS—skin cancer	1.77e-05	0.000252	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—IL6—skin cancer	1.69e-05	0.000241	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—HRAS—skin cancer	1.63e-05	0.000232	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—NRAS—skin cancer	1.56e-05	0.000222	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—IL6—skin cancer	1.56e-05	0.000222	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—KRAS—skin cancer	1.34e-05	0.000191	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—NRAS—skin cancer	1.32e-05	0.000188	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—TP53—skin cancer	1.19e-05	0.00017	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—HRAS—skin cancer	1.14e-05	0.000163	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—KRAS—skin cancer	1.14e-05	0.000162	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—IL6—skin cancer	1.09e-05	0.000156	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—HRAS—skin cancer	9.65e-06	0.000138	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—IL6—skin cancer	9.24e-06	0.000132	CbGpPWpGaD
